Trade Entero Therapeutics Inc - ENTO CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0463 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.9274 |
| Open | 0.9678 |
| 1-Year Change | 71.08% |
| Day's Range | 0.7429 - 0.9928 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 0.9429 | -0.0400 | -4.07% | 0.9829 | 0.9829 | 0.9274 |
| Jul 24, 2024 | 0.9929 | 0.0000 | 0.00% | 0.9929 | 1.0229 | 0.9929 |
| Jul 23, 2024 | 0.9929 | 0.0000 | 0.00% | 0.9929 | 1.0429 | 0.9529 |
| Jul 22, 2024 | 1.0129 | 0.0455 | 4.70% | 0.9674 | 1.0329 | 0.9674 |
| Jul 19, 2024 | 0.9769 | -0.0160 | -1.61% | 0.9929 | 1.0129 | 0.9632 |
| Jul 18, 2024 | 0.9530 | -0.0053 | -0.55% | 0.9583 | 1.0529 | 0.9529 |
| Jul 17, 2024 | 1.0029 | 0.0000 | 0.00% | 1.0029 | 1.0129 | 0.9529 |
| Jul 16, 2024 | 1.0129 | 0.0700 | 7.42% | 0.9429 | 1.0529 | 0.9388 |
| Jul 15, 2024 | 0.9425 | -0.0904 | -8.75% | 1.0329 | 1.0329 | 0.9045 |
| Jul 12, 2024 | 1.0529 | -0.0600 | -5.39% | 1.1129 | 1.1129 | 1.0229 |
| Jul 11, 2024 | 1.1029 | 0.0600 | 5.75% | 1.0429 | 1.1029 | 1.0229 |
| Jul 10, 2024 | 1.0929 | -0.0400 | -3.53% | 1.1329 | 1.2129 | 1.0529 |
| Jul 9, 2024 | 1.1729 | 0.1700 | 16.95% | 1.0029 | 1.2129 | 1.0029 |
| Jul 8, 2024 | 1.0229 | 0.0200 | 1.99% | 1.0029 | 1.0529 | 0.9929 |
| Jul 5, 2024 | 1.0429 | 0.0700 | 7.19% | 0.9729 | 1.0529 | 0.9729 |
| Jul 3, 2024 | 0.9769 | 0.0030 | 0.31% | 0.9739 | 0.9869 | 0.9739 |
| Jul 2, 2024 | 0.9730 | -0.1499 | -13.35% | 1.1229 | 1.1229 | 0.9429 |
| Jul 1, 2024 | 1.1029 | -0.0900 | -7.54% | 1.1929 | 1.1929 | 0.9829 |
| Jun 28, 2024 | 1.2229 | -0.0200 | -1.61% | 1.2429 | 1.2729 | 1.1829 |
| Jun 27, 2024 | 1.1929 | -0.3100 | -20.63% | 1.5029 | 1.5229 | 1.0929 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
First Wave BioPharma, Inc. Company profile
About First Wave BioPharma Inc
First Wave BioPharma, Inc., formerly AzurRx BioPharma, Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. It is focused on advancing a therapeutic development pipeline built around its two technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The Company's niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 immune checkpoint inhibitor-associated colitis and diarrhea in advanced oncology patients. It is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
Financial summary
BRIEF: For the nine months ended 30 September 2021, First Wave BioPharma Inc revenues was not reported. Net loss applicable to common stockholders increased from $23.4M to $73.2M. Higher net loss reflects Research and development expenses - Bala increase of 85% to $8.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$8.35 to -$10.31.
| Industry: | Biotechnology & Medical Research (NEC) |
777 Yamato Road
Suite 502
BOCA RATON
FLORIDA 33431
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com